Biochemical and biophysical comparison of cleaved and uncleaved soluble, trimeric HIV-1 envelope glycoproteins

Virology

Volumn 385, Issue 1, 2009, Pages 275-281

  Dey, Antu K ^a   David, Kathryn B ^a   Lu, Min ^a   Moore, John P ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Cleavage; Env; gp140 trimers; HIV 1

Indexed keywords

ANTIGEN; CD4 ANTIGEN; EPITOPE; GLYCOPROTEIN GP 140; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; VACCINE; VIRUS ENVELOPE PROTEIN;

ANTIGEN EXPRESSION; ANTIGEN STRUCTURE; ANTIGENICITY; ARTICLE; BIOCHEMICAL COMPOSITION; BIOPHYSICS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOPRECIPITATION; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; RNA CLEAVAGE; ULTRACENTRIFUGATION; WESTERN BLOTTING;

CELL LINE; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GLYCOPROTEINS; HIV-1; HUMANS; PROTEIN MULTIMERIZATION; PROTEIN STABILITY; ULTRACENTRIFUGATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 60349105588     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2008.12.009     Document Type: Article

References (41)

1. Allaway G.P., Davis-Bruno K.L., Beaudry G.A., Garcia E.B., Wong E.L., Ryder A.M., Hasel K.W., Gauduin M.C., Koup R.A., McDougal J.S., et al. Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates. AIDS Res. Hum. Retrovir. 11 5 (1995) 533-539
2. Beddows S., Franti M., Dey A.K., Kirschner M., Iyer S.P., Fisch D.C., Ketas T., Yuste E., Desrosiers R.C., Klasse P.J., Maddon P.J., Olson W.C., and Moore J.P. A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120. Virology 360 2 (2007) 329-340
3. Binley J.M., Sanders R.W., Clas B., Schuelke N., Master A., Guo Y., Kajumo F., Anselma D.J., Maddon P.J., Olson W.C., and Moore J.P. A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure. J. Virol. 74 2 (2000) 627-643
4. Binley J.M., Sanders R.W., Master A., Cayanan C.S., Wiley C.L., Schiffner L., Travis B., Kuhmann S., Burton D.R., Hu S.L., Olson W.C., and Moore J.P. Enhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteins. J. Virol. 76 6 (2002) 2606-2616
5. Binley J.M., Wrin T., Korber B., Zwick M.B., Wang M., Chappey C., Stiegler G., Kunert R., Zolla-Pazner S., Katinger H., Petropoulos C.J., and Burton D.R. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J. Virol. 78 23 (2004) 13232-13252
6. Bos E.C., Luytjes W., and Spaan W.J. The function of the spike protein of mouse hepatitis virus strain A59 can be studied on virus-like particles: cleavage is not required for infectivity. J. Virol. 71 12 (1997) 9427-9433
7. Burton D.R., Barbas III C.F., Persson M.A., Koenig S., Chanock R.M., and Lerner R.A. A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals. Proc. Natl. Acad. Sci. U. S. A. 88 22 (1991) 10134-10137
8. Burton D.R., Stanfield R.L., and Wilson I.A. Antibody vs. HIV in a clash of evolutionary titans. Proc. Natl. Acad. Sci. U. S. A. 102 42 (2005) 14943-14948
9. Cavacini L.A., Emes C.L., Wisnewski A.V., Power J., Lewis G., Montefiori D., and Posner M.R. Functional and molecular characterization of human monoclonal antibody reactive with the immunodominant region of HIV type 1 glycoprotein 41. AIDS Res. Hum. Retrovir. 14 14 (1998) 1271-1280
10. Cavacini L., Duval M., Song L., Sangster R., Xiang S.H., Sodroski J., and Posner M. Conformational changes in Env oligomer induced by an antibody dependent on the V3 loop base. Aids 17 5 (2003) 685-689
11. Dey A.K., David K.B., Klasse P.J., and Moore J.P. Specific amino acids in the N-terminus of the gp41 ectodomain contribute to the stabilization of a soluble, cleaved gp140 envelope glycoprotein from human immunodeficiency virus type 1. Virology 360 1 (2007) 199-208
12. Duval M., Posner M.R., and Cavacini L.A. A bispecific antibody composed of a nonneutralizing antibody to the gp41 immunodominant region and an anti-CD89 antibody directs broad human immunodeficiency virus destruction by neutrophils. J. Virol. 82 9 (2008) 4671-4674
13. Earl P.L., Broder C.C., Doms R.W., and Moss B. Epitope map of human immunodeficiency virus type 1 gp41 derived from 47 monoclonal antibodies produced by immunization with oligomeric envelope protein. J. Virol. 71 4 (1997) 2674-2684
14. Eggink D., Melchers M., and Sanders R.W. Antibodies to HIV-1: aiming at the right target. Trends Microbiol. 15 7 (2007) 291-294
15. Ferlenghi I., Gowen B., de Haas F., Mancini E.J., Garoff H., Sjoberg M., and Fuller S.D. The first step: activation of the Semliki Forest virus spike protein precursor causes a localized conformational change in the trimeric spike. J. Mol. Biol. 283 1 (1998) 71-81
16. Haynes B.F., Fleming J., St Clair E.W., Katinger H., Stiegler G., Kunert R., Robinson J., Scearce R.M., Plonk K., Staats H.F., Ortel T.L., Liao H.X., and Alam S.M. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 308 5730 (2005) 1906-1908
17. Hingley S.T., Leparc-Goffart I., and Weiss S.R. The spike protein of murine coronavirus mouse hepatitis virus strain A59 is not cleaved in primary glial cells and primary hepatocytes. J. Virol. 72 2 (1998) 1606-1609
18. Jeffs S.A., Goriup S., Kebble B., Crane D., Bolgiano B., Sattentau Q., Jones S., and Holmes H. Expression and characterisation of recombinant oligomeric envelope glycoproteins derived from primary isolates of HIV-1. Vaccine 22 8 (2004) 1032-1046
19. Johnson M.L., Correia J.J., Yphantis D.A., and Halvorson H.R. Analysis of data from the analytical ultracentrifuge by nonlinear least-squares techniques. Biophys. J. 36 3 (1981) 575-588
20. Laue T.M., Shah B.D., Ridgeway T.M., and Pelletier S.L. Computer-aided interpretation of analytical sedimentation data for proteins. In: Harding S.E., Rowe A.J., and Horton J.C. (Eds). Analytical ultracentrifugation in biochemistry and polymer science (1992), Royal Society of Chemistry, Cambridge, United Kingdom
21. Liu J., Bartesaghi A., Borgnia M.J., Sapiro G., and Subramaniam S. Molecular architecture of native HIV-1 gp120 trimers. Nature 455 7209 (2008) 109-113
22. Moore P.L., Crooks E.T., Porter L., Zhu P., Cayanan C.S., Grise H., Corcoran P., Zwick M.B., Franti M., Morris L., Roux K.H., Burton D.R., and Binley J.M. Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1. J. Virol. 80 5 (2006) 2515-2528
23. Pancera M., and Wyatt R. Selective recognition of oligomeric HIV-1 primary isolate envelope glycoproteins by potently neutralizing ligands requires efficient precursor cleavage. Virology 332 1 (2005) 145-156
24. Pantophlet R., Wilson I.A., and Burton D.R. Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine design. J. Virol. 77 10 (2003) 5889-5901
25. Russell D.L., Dalrymple J.M., and Johnston R.E. Sindbis virus mutations which coordinately affect glycoprotein processing, penetration, and virulence in mice. J. Virol. 63 4 (1989) 1619-1629
26. Sanders R.W., Vesanen M., Schuelke N., Master A., Schiffner L., Kalyanaraman R., Paluch M., Berkhout B., Maddon P.J., Olson W.C., Lu M., and Moore J.P. Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J. Virol. 76 17 (2002) 8875-8889
27. Sattentau Q.J., Zolla-Pazner S., and Poignard P. Epitope exposure on functional, oligomeric HIV-1 gp41 molecules. Virology 206 1 (1995) 713-717
28. Scanlan C.N., Pantophlet R., Wormald M.R., Ollmann Saphire E., Stanfield R., Wilson I.A., Katinger H., Dwek R.A., Rudd P.M., and Burton D.R. The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1 -> 2 mannose residues on the outer face of gp120. J. Virol. 76 14 (2002) 7306-7321
29. Schulke N., Vesanen M.S., Sanders R.W., Zhu P., Lu M., Anselma D.J., Villa A.R., Parren P.W., Binley J.M., Roux K.H., Maddon P.J., Moore J.P., and Olson W.C. Oligomeric and conformational properties of a proteolytically mature, disulfide-stabilized human immunodeficiency virus type 1 gp140 envelope glycoprotein. J. Virol. 76 15 (2002) 7760-7776
30. Selvarajah S., Puffer B., Pantophlet R., Law M., Doms R.W., and Burton D.R. Comparing antigenicity and immunogenicity of engineered gp120. J. Virol. 79 19 (2005) 12148-12163
31. Smit J.M., Klimstra W.B., Ryman K.D., Bittman R., Johnston R.E., and Wilschut J. PE2 cleavage mutants of Sindbis virus: correlation between viral infectivity and pH-dependent membrane fusion activation of the spike heterodimer. J. Virol. 75 22 (2001) 11196-11204
32. Stamatatos L., Lim M., and Cheng-Mayer C. Generation and structural analysis of soluble oligomeric gp140 envelope proteins derived from neutralization-resistant and neutralization-susceptible primary HIV type 1 isolates. AIDS Res. Hum. Retrovir. 16 10 (2000) 981-994
33. Stevens J., Corper A.L., Basler C.F., Taubenberger J.K., Palese P., and Wilson I.A. Structure of the uncleaved human H1 hemagglutinin from the extinct 1918 influenza virus. Science 303 5665 (2004) 1866-1870
34. Thali M., Moore J.P., Furman C., Charles M., Ho D.D., Robinson J., and Sodroski J. Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. J. Virol. 67 7 (1993) 3978-3988
35. Trkola A., Purtscher M., Muster T., Ballaun C., Buchacher A., Sullivan N., Srinivasan K., Sodroski J., Moore J.P., and Katinger H. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol. 70 2 (1996) 1100-1108
36. Watanabe M., Hirano A., Stenglein S., Nelson J., Thomas G., and Wong T.C. Engineered serine protease inhibitor prevents furin-catalyzed activation of the fusion glycoprotein and production of infectious measles virus. J. Virol. 69 5 (1995) 3206-3210
37. Wool-Lewis R.J., and Bates P. Endoproteolytic processing of the ebola virus envelope glycoprotein: cleavage is not required for function. J. Virol. 73 2 (1999) 1419-1426
38. Yang X., Florin L., Farzan M., Kolchinsky P., Kwong P.D., Sodroski J., and Wyatt R. Modifications that stabilize human immunodeficiency virus envelope glycoprotein trimers in solution. J. Virol. 74 10 (2000) 4746-4754
39. Yang O.O., Nguyen P.T., Kalams S.A., Dorfman T., Gottlinger H.G., Stewart S., Chen I.S., Threlkeld S., and Walker B.D. Nef-mediated resistance of human immunodeficiency virus type 1 to antiviral cytotoxic T lymphocytes. J. Virol. 76 4 (2002) 1626-1631
40. Zhou T., Xu L., Dey B., Hessell A.J., Van Ryk D., Xiang S.H., Yang X., Zhang M.Y., Zwick M.B., Arthos J., Burton D.R., Dimitrov D.S., Sodroski J., Wyatt R., Nabel G.J., and Kwong P.D. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 445 7129 (2007) 732-737
41. Zwick M.B., Jensen R., Church S., Wang M., Stiegler G., Kunert R., Katinger H., and Burton D.R. Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1. J. Virol. 79 2 (2005) 1252-1261